Ribo Life Science and Ribocure Expand Horizons with Madrigal
In an exciting development, Suzhou Ribo Life Science Co., Ltd. (HKEX: 06938) and its subsidiary Ribocure Pharmaceuticals AB have forged an exclusive worldwide licensing deal with Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL). The agreement centers around six promising pre-clinical small interfering RNA (siRNA) programs that target metabolic dysfunction-associated steatohepatitis (MASH).
Harnessing Innovative Technology
Under this collaboration, Ribo will utilize its GalSTARTM platform, known for effective liver targeting, to pioneer new treatments for MASH. The licensing agreement encompasses several existing pre-clinical assets from Ribo, paving the way for the possibility of future collaborative efforts on new siRNA programs aimed at tackling MASH with innovative bi-specific siRNAs. These agents are designed to simultaneously target two disease-causing genes, showcasing Ribo’s advanced siRNA chemical modification methods.
Voices from Leadership
Dr. Zicai Liang, CEO of Ribo, expressed enthusiasm for the partnership, emphasizing the combination of Madrigal's extensive expertise and Ribo’s siRNA capabilities to create life-changing therapies for patients battling liver disease.
Echoing this sentiment, Dr. Li-Ming Gan, CEO of Ribocure and co-CEO of Ribo, stated, “Collaborating with the team that successfully launched the world’s first medication for MASH is incredibly promising. Our aim is to broaden the therapeutic landscape for MASH, leveraging our proprietary siRNA platform to devise multi-mechanistic therapies that are both targeted and effective.”
Understanding Financial Aspects
The financial structure of the agreement reflects the significant potential of this collaboration. Madrigal receives exclusive global rights to develop, manufacture, and market various siRNA assets from Ribo. The initial payment to Ribo stands at US$60 million, with total potential payments surmounting to US$4.4 billion contingent upon achieving specific development, regulatory, and commercial milestones, in addition to potential royalties based on net sales.
Insights on MASH
MASH, previously referred to as nonalcoholic steatohepatitis (NASH), is a critical liver ailment that can deteriorate into severe complications such as cirrhosis, liver cancer, or even the necessity for liver transplants, contributing to premature mortality. Notably, MASH is notably prevalent among women and ranks as the second leading cause of liver transplants in general within the country.
As patients transition to MASH characterized by moderate to advanced liver fibrosis, the risk of severe liver-related outcomes significantly escalates—evidence suggests a 10-17 times greater likelihood of liver-related mortality compared to non-fibrotic individuals. Those who advance to cirrhosis face a staggering 42-fold increase in the risk of liver-related fatalities, highlighting the critical necessity for effective treatments for MASH before severe complications arise. Additionally, MASH acts as an independent contributor to cardiovascular diseases, which is frequently the leading cause of death in patients.
The Future Landscape for MASH
As awareness of MASH continues to rise, along with its prevalence, it is anticipated that the number of diagnosed patients experiencing moderate to advanced fibrosis or compensated MASH cirrhosis will surge substantially. This presents an opportunity for innovation and growth in therapeutic developments in this domain.
Company Background
Founded on innovative research, Suzhou Ribo Life Science Co., Ltd. is a clinical-stage R&D company dedicated to crafting nucleic acid drugs and allied products via RNA interference technology. With a robust pipeline and vertically integrated technological platforms, Ribo is committed to addressing critical medical needs.
As a significant arm of Suzhou Ribo Life Science, Ribocure is focused on the global development of pioneering oligonucleotide therapies and enhancing its research capabilities to fulfill clinical trial requirements. Their mission is centered on advancing siRNA drug development in response to pressing global health demands.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), is committed to innovating therapeutic options for MASH, a liver condition fraught with significant unmet medical requirements. Their medication, Rezdiffra (resmetirom), represents a groundbreaking advancement as the first oral THR-? agonist specifically aimed at addressing underlying causes of MASH. Rezdiffra has received approvals from the FDA and European Commission as a treatment for MASH with moderate to advanced fibrosis, and an ongoing Phase 3 trial is assessing its efficacy for treating compensated MASH cirrhosis.
Frequently Asked Questions
What is the significance of the partnership between Ribo and Madrigal?
This partnership aims to capitalize on Ribo’s siRNA technology to advance treatments specifically for MASH, addressing a significant unmet medical need.
What are siRNA therapeutics?
siRNA therapeutics are designed to silence specific genes that contribute to disease, enabling targeted treatment options for various health conditions, including MASH.
What financial aspects were included in the licensing agreement?
Ribo is set to receive an upfront payment of US$60 million, with the potential for cumulative payments of up to US$4.4 billion based on development and regulatory achievements.
Why is MASH a critical focus for these companies?
MASH poses serious health risks and is increasingly prevalent, making the development of effective therapies essential to reduce liver-related health complications.
How does the GalSTARTM platform work in this context?
The GalSTARTM platform is utilized to target liver cells specifically, enhancing the therapeutic efficacy of siRNA interventions aimed at treating MASH.
